A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer

被引:19
作者
Huang, Wenhai [1 ]
Huang, Hao [2 ]
Zhang, Shuishen [3 ]
Wang, Xueping [4 ]
Ouyang, Juan [2 ]
Lin, Zhichao [1 ]
Chen, Peisong [2 ]
机构
[1] Jiangmen Ctr Hosp, Dept Thorac Surg, 23 Haibang St,North St, Jiangmen 529030, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Dept Lab Med, Affiliated Hosp 1, 58 Zhongshan Rd II, Guangzhou 510080, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Dept Thorac Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Dept Lab Med, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Guangdong, Peoples R China
关键词
lung cancer; diagnosis; stature homeobox 2; total methylation; decision tree;
D O I
10.1177/1073274820969703
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Lung cancer (LC) is often accompanied by significant methylation abnormalities. This study aimed to develop a decision tree (DT) accompanied the stature homeobox 2 gene (SHOX2) / prostaglandin E receptor 4 (PTGER4) gene DNA methylation with traditional tumor marker in the differential diagnosis of benign and malignant lung nodule. Methods: We performed a study with 104 patients enrolled in the LC group and 36 patients in the benign lung diseases group. All the clinical data of these patients were collected through electronic medical record. Total Methylation (TM) status of both SHOX2 and PTGER4 was defined as methylation levels of SHOX2 plus methylation levels of PTGER4. One-way analysis was used to compare the concentrations of serum samples and t-test was used to compare pairwise mean values between groups. Receiver operating curve (ROC) was used to evaluate the diagnostic value. Furthermore, the strategy was validated in 19 LC patients and 11 patients with benign lung diseases. Results: There were significant differences between the concentration of neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA21 -1) and the methylation levels of SHOX2, PTGER4 and TM in lung benign diseases and cancer group. The AUCs of NSE, CEA, CYFRA21 -1, Methylation SHOX2, Methylation PTGER4 and TM were 0.721 (95% CI: 0.627-0.816), 0.753 (95% CI: 0.673-0.833) and 0.778(95% CI: 0.700-0.856), 0.851(0.786-0.916), 0.847(0.780-0.913) and 0.861(0.800-0.922) respectively. We developed a DT model with TM and CYFRA21 -1 used in this study, and the area under the curve (AUC) of DT was 0.921 and the sensitivity up to 0.856. In the validation cohort, the AUC of SHOX2, PTGER4 and TM was also much higher than traditional serum markers. Conclusions: Our results indicated that the DT model calculated from the TM and CYFRA21 -1 can accurately classify LC and benign diseases, which showed better diagnostic performance than traditional serum parameter.
引用
收藏
页数:8
相关论文
共 31 条
[1]   Case histories Lung cancer [J].
Barnett, Richard .
LANCET, 2017, 390 (10098) :928-928
[2]   Epigenetics in endometrial carcinogenesis - part 1: DNA methylation [J].
Bartosch, Carla ;
Lopes, Jose Manuel ;
Jeronimo, Carmen .
EPIGENOMICS, 2017, 9 (05) :737-755
[3]   Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract [J].
Branchi, V. ;
Schaefer, P. ;
Semaan, A. ;
Kania, A. ;
Lingohr, P. ;
Kalff, J. C. ;
Schaefer, N. ;
Kristiansen, G. ;
Dietrich, D. ;
Matthaei, H. .
CLINICAL EPIGENETICS, 2016, 8
[4]   Lung Cancer [J].
Brody, Herb .
NATURE, 2014, 513 (7517) :S1-S1
[5]   Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers [J].
Cheng, Jinming ;
Wei, Dongkai ;
Ji, Yuan ;
Chen, Lingli ;
Yang, Liguang ;
Li, Guang ;
Wu, Leilei ;
Hou, Ting ;
Xie, Lu ;
Ding, Guohui ;
Li, Hong ;
Li, Yixue .
GENOME MEDICINE, 2018, 10
[6]   Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer [J].
Church, Timothy Robert ;
Wandell, Michael ;
Lofton-Day, Catherine ;
Mongin, Steven J. ;
Burger, Matthias ;
Payne, Shannon R. ;
Castanos-Velez, Esmeralda ;
Blumenstein, Brent A. ;
Roesch, Thomas ;
Osborn, Neal ;
Snover, Dale ;
Day, Robert W. ;
Ransohoff, David F. .
GUT, 2014, 63 (02) :317-325
[7]  
da Costa Daniel J, 2018, Am J Respir Crit Care Med, V198, P667, DOI 10.1164/rccm.201801-0107RR
[8]   Lung cancer screening and its continuous risk assessment [J].
de Koning, Harry J. .
LANCET ONCOLOGY, 2017, 18 (11) :1434-1436
[9]   Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates [J].
Dietrich, Dimo ;
Kneip, Christoph ;
Raji, Olaide ;
Lloglou, Triantafillos ;
Seegebarth, Anke ;
Schlegel, Thomas ;
Flemming, Nadja ;
Rausch, Sebastian ;
Distler, Juergen ;
Fleischhacker, Michael ;
Schmidt, Bernd ;
Giles, Thomas ;
Walshaw, Martin ;
Warburton, Chris ;
Liebenberg, Volker ;
Field, John K. .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 40 (03) :825-832
[10]   Aberrant DNA methylation as a cancer-inducing mechanism [J].
Esteller, M .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2005, 45 :629-656